Abstract. Breast cancer is the most prevalent cancer in women worldwide. Triple-negative breast cancer (TNBC) is characterized by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. It is the most aggressive subtype of breast cancer and accounts for 12-20% of all breast cancer cases. TNBC is associated with younger age of onset, greater metastatic potential, higher incidence of relapse, and lower overall survival rates. Based on molecular phenotype, TNBC has been classified into six subtypes (BL1, BL2, M, MES, LAR, and IM). TNBC treatment is challenging due to its heterogeneity, highly invasive nature, and relatively poor therapeutics response. Chemotherapy and radiotherapy are conventional strategies for the treatment of TNBC. Recent research in TNBC and mechanistic understanding of disease pathogenesis using cutting-edge technologies has led to the unfolding of new lines of therapies that have been incorporated into clinical practice. Poly (ADP-ribose) polymerase and immune checkpoint inhibitors have made their way to the current TNBC treatment paradigm. This review focuses on the classification, features, and treatment progress in TNBC. Histological subtypes connected to recurrence, molecular classification of TNBC, targeted therapy for early and advanced TNBC, and advances in non-coding RNA in therapy are the key highlights in this review.

1. Introduction

Breast cancer is a heterogeneous disease with varying biological and clinical characteristics. It is the most common cancer among women worldwide, accounting for 25% of all cancer cases (1). According to GLOBOCAN 2020, the incidence and mortality of breast cancer reported worldwide were 34,65,951 new cases and 11,21,413 deaths, respectively; in India, 1,204,532 new cases and 436,417 deaths were recorded in 2020 (2).

Immunohistochemical analysis of breast tumors is the gold-standard method used in clinics to classify them based on the hormone receptor expression for improved therapeutic decisions. Based on this, breast cancer can be broadly grouped into five types, namely: i) Progesterone receptor (PR)-positive, estrogen receptor (ER)-positive and human epidermal growth factor 2 (Her2)-negative (luminal A); ii) ER-positive, PR-positive/negative and Her2-positive (luminal B); iii) Her2-overexpressing, ER- and PR-negative; iv) ER-, PR- and Her2-negative (basal-like or triple-negative), and v) normal-like (expression status similar to luminal A and resemble normal breast profile) (3-5). Additionally, molecular breast cancer analysis identified a distinctive phenotype with low claudin expression, immune receptor, and EMT markers expression (6). Cancer types with the claudin-low phenotype are highly metastatic and associated with poor prognosis (7). Her2-overexpressing cancer also displays high metastasis and poor prognosis (8). Among ER-positive subtypes, luminal B is associated with a significantly worse prognosis than luminal A (9,10). Patients with basal subtypes of cancer with BRCA1 mutations have a poor prognosis (9).
Based on specific gene expression patterns, breast cancers are categorized into five intrinsic or molecular subtypes. Among the intrinsic subtypes, basal-like triple-negative breast cancer (TNBC) accounts for 12-20% of breast cancers (11). TNBC has drawn specific attention due to the lack of expression of all three receptors (ER, PR, and Her2). Thus, it cannot be treated using anti-estrogen hormonal therapies or trastuzumab (12). Morphologically, TNBC is characterized by hyperdense masses without calcification, usually occurring in women <50 years of age. Histological features include significant lymphocyte infiltration, central necrosis, pushing tumor borders, and fibrosis (13). Cytokeratins, fascin, epidermal growth factor receptor (EGFR), caveolin, and vimentin are usually expressed in basal-like TNBC (14,15). TNBC is challenging to treat, as it is quite complex due to poor cell differentiation, molecular heterogeneity, and rapid metastasis, often leading to chemoresistance and recurrence of the disease (16). Fast relapse and invasions are common features of TNBC tumors and show poor prognosis (17). Recent advances in omics technologies have provided insight into the molecular mechanisms underlying TNBC (18). The present review focuses on the different subtypes of TNBC and therapeutic approaches currently employed in the treatment of TNBC.

2. Histology-guided classification of TNBC

Histologically, most TNBC is categorized as no special type (IDC-NST) (17). Most IDC is characterized by pleomorphic cells with prominent nucleoli. The cells are organized into diffuse sheets, cords, nests with ductal differentiation. The rest of the tumors are categorized into 47 specific subtypes, such as invasive lobular carcinoma (relatively common), metaplastic carcinoma, medullary carcinoma, mucinous carcinoma, adenoid cystic carcinoma, secretory carcinoma, acinic cell carcinoma, neuroendocrine tumors, as well as the rarest glycogen-rich clear cell carcinoma (19,20).

Among these specific subtypes (Fig. 1), medullary breast carcinoma occurs in <1% of patients and shows distinctive features, such as high lymphoplasmacytic infiltration, overexpression of BCLG (a pro-apoptotic gene); it bears more losses of heterozygosity than other subtypes and is immunomodulatory (21,22). It is associated with better outcomes compared with other TNBC subtypes (22). Metaplastic carcinoma presents unique pathologic features, where the glandular component may be partially or completely replaced by a non-glandular component(s), and based on their differentiation status further divided into i) Squamous type, tumor with keratinization and squamous differentiation; ii) matrix-producing type, tumor with more cells in the periphery; iii) mixed type, tumor showing both squamous differentiation and large high-grade cells with pleomorphic nuclei; and iv) spindle-cell type, tumor with storiform-like spindle cells. These metaplastic tumors harbor mutations in the PIK3CA, Wnt (Wingless-Type MMTV Integration Site Family) signaling pathway genes and display a unique copy number alteration pattern (23-25). Adenoid cystic carcinoma (ACC) is characterized by the presence of dividing epithelial cells and myoepithelial cells producing mucinous membrane. ACC occurs in 0.1% of patients with basal-like features (26,27) and expresses markers, such as cytokeratin 5, 6, 14 and 17 (28). Secretory carcinoma is characterized by microcystic, solid and tubular architecture and presence of vacuolated tumor cells producing intracellular and extracellular secretions. It occurs in <1% of the patients and is referred to as juvenile carcinoma, as it is common in adolescents and often reported to have favorable outcomes. It is also characterized by ETV6-NTRK3 fusion (29-31). The rarest among all the subtypes is glycogen-rich clear cell carcinoma, in which the tumors appear in sheets and cells are polygonal in shape, with a clear cytoplasm and the presence of glycogen (32). In these sheets, there are areas of lymphocytic infiltration and plasma cells.

Among the histological subtypes, adenoid cystic carcinoma has a median recurrence of only 2 months, and metaplastic carcinoma has ~9.9 months (33), compared to IDC-NST and matrix-producing metastatic carcinoma, which are less aggressive, with 34 and 31.4 months of median time to recurrence, respectively (20).

Although the histological assessments were pointing to the presence of WBCs in and around the TNBC subtypes, focus on the presence of WBCs has led to the identification of TILs and TAMs, which are the parameters defining prognosis and therapy of TNBC. The TNBCs might be immunogenic due to mutations that lead to aberrant protein expression on the cell membrane (34). Tumor-infiltrating lymphocytes (TILs) are white blood cells that migrate towards the tumor from the bloodstream via the newly formed blood vessels (angiogenesis), which cancer cells use for their nutritional and oxygen requirements (35). They consist of a mixture of B cells, macrophages, natural killer cells and are dominated by T cells (35). TILs are present in ~20% of TNBC tumors and carry a pivotal prognostic and predictive value (36). The presence of TILs indicates a good prognosis (37). High number of TILs indicate that there is an equilibrium between the immune status and cancer (38). The ratio of cancer cells: TILs is tilted towards TILs after surgical removal of a tumor, resulting in an improved prognosis in TNBC (38). A high mutation load and clonal heterogeneity are associated with a low number of TILs, which may provide an escape route to tumor cells from immune surveillance (39). However, in addition to TILs, the tumor microenvironment components also influence the outcome of patients with TNBC (39). Relapsing patients with TNBC have been shown to have low levels of TILs and a high number of CD163+ tumor-associated macrophages (TAMs) compared with that of patients without relapse (39). High levels of CD8+ T cells may reflect improved sensitivity to chemotherapy, whereas high levels of TAMs correlate with poor patient outcomes (36). Nevertheless, a previous study in TNBC has reported paradoxical findings, with high levels of CD8+ T cells in the tumor stroma leading to the low infiltration of the tumor epithelium, thereby indicating a poor outcome (40). Therefore, immunohistological assessment for TILs or TAMs will help develop immunotherapies detailed in section 7.

3. Multiomics-guided molecular classification of TNBC

Profiling based on gene expression has led to improved insight into tumor heterogeneity at the molecular level and has generated an impartial classification (Fig. 1). The PAM50
A microarray set of 50 genes is used to identify breast cancer intrinsic subtypes (41). A set of 374 TNBC samples taken from 14 microarray datasets was analyzed to characterize TNBC subtypes using PAM50. The results from this analysis categorized most of the TNBC as basal-like (80.6%). The rest of the tumours were classified as Her2-positive (0.2%), normal-like (14.6%), luminal B (3.5%) and luminal A (1.1%) (Table I) (41).

Lehmann et al (42) performed gene expression profiling of 2,188 genes from 587 patients with TNBC and classified TNBC into six new groups, namely, basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), luminal androgen receptor (LAR), mesenchymal stem cell-like (MSL) and mesenchymal (M). The rest was classified as an unstable type (UNS/UNC). Each subtype had its characteristic feature. Basal-like was the most common type of TNBC (BL1, 22%; BL2, 12%) and was characterized by high Ki67 and DNA damage response levels. The IM subtype (18%) had basal-like characteristics with activation of IFNα and IFNγ signaling and high cytotoxic T-lymphocyte associated protein 4 gene expression. Mesenchymal subtypes (M, 21%; MSL, 10%), along with cell differentiation pathways, showed deregulation of EGFR, calcium signaling, MAPK, and PI3K signaling. In the LAR subtype (9%), an ~10-fold increase in androgen receptor (AR) expression was seen, compared with other subtypes. Activation of various pathways, such as steroid synthesis and FOXA1 and ERBB signaling, were observed in this subtype (Table I) (42,43).

Burststein et al (43) used a non-negative matrix factorization method to derive a panel consisting of 80 core genes that divided TNBC into four subtypes, luminal-AR (LAR), mesenchymal (MES), basal-like immune-suppressed (BLIS), and basal-like immune-activated (BLIA). BLIA has the best disease-free survival outcome compared to other subtypes (44). Based on DNA copy number, these subtypes can be placed into two groups, LAR or others (Table I) (31).

Liu et al (45) performed mRNA and long non-coding RNA (lncRNA) expression analysis in 165 TNBC tumor samples at Fudan University Shanghai Cancer Centre. The tumor samples were categorized into four subtypes (IM, LAR, MES, and BLIS subtypes), consistent with the classification by Burststein et al (43). The IM subtype comprised of genes related to immune functions such as CCR2, CXCL13, CXCL11, CD1C, CXCL10, and CCL5, along with ENST00000443397 long ncRNA. In contrast, the LAR subtype had enrichment of hormone regulation signaling and ENST00000447908 lncRNA (45). The MES subtype expressed IncRNA NR_003221 together with genes and pathways that promoted epithelial-to-mesenchymal (EMT) transition. Pathways and molecules such as DNA repair, replication, and mitosis, IncRNA TCONS_0000027 were enriched in the BLIS subtype (45,46).

Genomic/transcriptomic data from a set of 997 primary tumors were extracted, and an integrated analysis was performed by Curtis et al (47). A set of 995 tumors from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort was used as a validation set that divided TNBC into ten groups, named Integrated Clusters (IntClust) 1-10 (47). Basal-like breast cancer mostly fell in IntClust 4 and 10 (~80%). IntClust 4 is known to have greater TIL counts, while IntClust 10 subtype can display genomic instability and chromosomal aberrations (Table I) (47-49).
| First author, year | Country or region | Method | Classification | Features/Pathways enriched | (Refs.) |
|--------------------|-------------------|--------|----------------|---------------------------|---------|
| Perue et al, 2000  | Norway and Stanford | Microarray ScanArray 3000; PAM50 | Luminal A | Estrogen receptor and transcription factors (GATA, X-box binding proteins, EST downregulation) | (3)     |
|                    |                   |        | Luminal B     | Estrogen receptor and transcription factors (GATA, X-box binding proteins) |         |
|                    |                   |        | Her2⁺         | ERBB2 and GRB7 overexpression |         |
|                    |                   |        | Normal-like   | Overexpression of adipose tissue and other non-epithelial cell types expressed genes |         |
|                    |                   |        | Basal-like    | Keratin 5 and -17, laminin and fatty acid binding protein 7 overexpression |         |
| Lehmann et al, 2014| Sweden, UK, Netherlands, USA, Singapore/Belgium | Affymetrix | Basal-like 1  | Cell cycle, DNA replication reactome, RNA polymerase, and | (42)    |
|                    |                   |        | Luminal Basal-like 2 | EGF pathway, NGF pathway, MET pathway, Wnt/β-catenin, and IGF1R pathway |         |
|                    |                   |        | Mesenchymal   | Cell motility, ECM receptor interaction and cell differentiation pathways |         |
|                    |                   |        | Mesenchymal stem cell-like | Cell motility, cellular differentiation, growth pathway, inositol phosphate metabolism, EGFR, PDGF, calcium signalling, |         |
|                    |                   |        | Immunomodulatory subtype | Immune cell signalling cytokine signalling, antigen processing and presentation, and signalling through core immune signal transduction pathways |         |
|                    |                   |        | Androgen receptor subtype | Steroid synthesis, porphyrin metabolism, and androgen/oestrogen metabolism |         |
| Curtis et al, 2012 | UK and Canada (METABRIC) | Affymetrix; Illumina HT-12 v3 platform | Integrative cluster 1 | 17q23/20q cis-acting | (47)    |
|                    |                   |        | Integrative cluster 2 | 11q13/14 cis-acting |         |
|                    |                   |        | Integrative cluster 3 | Low genomic instability |         |
|                    |                   |        | Integrative cluster 4 | CNA-devoid |         |
|                    |                   |        | Integrative cluster 5 | ERBB2-amplified |         |
|                    |                   |        | Integrative cluster 6 | 8p12 cis-acting |         |
|                    |                   |        | Integrative cluster 7 | 16p gain/16q loss, 8q amplification |         |
|                    |                   |        | Integrative cluster 8 | 1q gain/16q loss |         |
|                    |                   |        | Integrative cluster 9 | 8q cis-acting/20q-amplified |         |
|                    |                   |        | Integrative cluster 10 | cis-acting alterations 5 loss/8q gain/10p gain/12p gain |         |
Table I. Continued.

| First author, year | Country or region      | Method      | Classification           | Features/Pathways enriched                                                                 | (Refs.) |
|--------------------|------------------------|-------------|--------------------------|------------------------------------------------------------------------------------------|---------|
| Burstein et al.,   | USA and European       | Affymetrix  | Luminal-AR               | androgen receptor, oestrogen receptor, prolactin, and ERBB4 signalling                    | (43)    |
| 2015               |                        |             | Mesenchymal              | cell cycle, mismatch repair and DNA damage networks, and hereditary breast cancer signalling pathways |
|                    |                        |             | Basal-like immune-       | downregulation of B cell, T cell and natural killer cell immune-regulating pathways and cytokine pathways |
|                    |                        |             | suppressed               |                                                                                              |
| Liu et al, 2016    | China                  | Affymetrix  | Immunomodulatory subtype | Cytokine-cytokine receptor interaction, T cell receptor signalling pathway, B cell receptor signalling pathway, chemokine signalling pathway |
|                    |                        |             | Luminal-AR               | Steroid hormone biosynthesis, Porphyrin and chlorophyll metabolism, PPAR signalling pathway, Androgen and oestrogen metabolism |
|                    |                        |             | Mesenchymal              | ECM-receptor interaction, Focal adhesion, TGF-β signalling pathway, ABC transporter, Adipocytokine signalling pathway |
|                    |                        |             | Basal-like immune-       | Mitotic cell cycle, Mitotic prometaphase, M phase of mitotic cell cycle, DNA replication, DNA repair |
|                    |                        |             | suppressed               |                                                                                              |
4. Molecular aberrations in TNBC

Through whole-exome and whole-genome data, it is evident that most of the genetic alterations in TNBC are copy number alterations and somatic mutations (40). The BRCA1 and BRCA2 tumor suppressor genes are required for the maintenance of genomic stability. These genes play a role in DNA repair and replication error control (50,51). A total of 10% of patients with TNBC are known to harbor germline mutations in BRCA1 or BRCA2 (12,26,27). The lifetime risk of breast cancer becomes 60-70% in the presence of such mutations (52). Gene alterations leading to homologous recombination (HR) defects other than germline BRCA mutations are termed ‘BRCAness’ (53). Moreover, ~35% of TNBC tumors show abnormalities in the HR pathway, making them sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors and DNA-damaging agents (54).

Other common mutations observed in TNBC patients include those in TP53 (50-60%) and PIK3CA (~10%) (18,42). An analysis from the Catalogue of Somatic Mutations in Cancer (COSMIC) database revealed that the top genes mutated in TNBC, apart from BRCA1/2, TP53, and PIK3CA, were RB1, PTEN, NOTCH1 and NOTCH2 (Fig. 2A). Among the point mutations observed, 34% of them were nonsense substitutions (where a base change leads to a stop codon in the DNA sequence), 21% were synonymous mutations (where a change in a base in the exon of a coding gene does not change the structure of the protein) (Fig. 2B). The rest of the mutations were missense mutations, frameshift insertion/deletions, and in-frame insertions/deletions. In the metastatic disease setting, genes from HR repair showed a larger frequency of biallelic loss-of-function mutations than in early TNBC (55).

Integrated analysis of The Cancer Genome Atlas (56) has demonstrated deletions in PTEN, DUSP4, and INPP4B involved in the PI3K-AKT pathway. Gene amplifications were seen in MYC, PIK3CA, KRAS, BRAF, FGFR, MET, and EGFR. Mutations in genes, such as ERBB2, AKT1, ATR, MAP3K1, CDKN2A, ATM, and NOTCH2 (18,42,51), were also observed. Based on the mutation signatures obtained from whole-genome sequencing of 560 tumors, TNBC could be classified into four mutation subtypes, namely, APOBEC-based signatures, HR deficiency-based signature (signature 3), ‘clock-like’ signatures (signatures 1 and 5), and mixed (no prominent signature) (56,57). These mutations suggest that DNA repair, the PI3K/AKT pathway, cell cycle checkpoints, and Notch signaling are possible druggable pathways in TNBC (58).

5. Circulating tumor cells (CTCs) in TNBC

Recently, much focus has been put on bringing liquid biopsies, such as circulating tumor cells (CTC) and circulating tumor DNA (ctDNA), into the clinical setting for diagnostic and prognostic use (59). CTCs are nucleated cancer cells present in the bloodstream that can be detected using techniques, such as reverse transcription-quantitative PCR, flow cytometry, and immunohistochemistry (60). Tumor cells that undergo necrosis or apoptosis release DNA fragments into the plasma are referred to as ctDNA (61). In breast cancer, ctDNA and CTCs have been studied as potential biomarkers for prognosis (60). Stover et al (62) performed studies in metastatic breast cancer patients receiving chemotherapy and identified an association between CTCs and ctDNA and tumor burden, indicating that these could be used to measure early-treatment response in patients. A retrospective study in 164 patients with metastatic TNBC revealed that >10% of patients with ctDNA had worse disease-free survival (62). A study by Bidard et al (63), with metastatic breast cancer, revealed that patients with CTC levels >5 per 7.5 ml were associated with lower progression-free survival (PFS) and OS compared with patients who had CTC levels <5 per 7.5 ml. Cristofanilli et al (64) reported that CTC counts could be utilized to classify metastatic patients into two groups. Patients with CTCs levels >5 per 7.5 ml were categorized as aggressive stage IV and those <5 per 7.5 ml as indolent stage IV (64). ctDNA has been associated with chemotherapy in studies by Riva et al (65), in which ctDNA-positive patients before and after chemotherapy experienced poor OS and disease-free survival (DFS). Additionally, Radovich et al (66) reported that patients with early-stage TNBC and positive ctDNA after chemotherapy had a higher risk of disease relapse. Therefore, liquid biopsies are being developed as a non-invasive method to study recurrence, treatment response, and survival in the clinical setting.

6. Conventional mode of treatment in TNBC

TNBC treatment involves a combination of surgery, radiotherapy, and chemotherapy. New methods, such as targeted therapy and immunotherapy, have been developed to improve patient survival and prognosis. Lumpectomy and mastectomy are the surgical procedures performed for TNBC patients and are usually followed by radiotherapy and chemotherapy (67). Neoadjuvant therapy is given before the surgery, which may help shrink the tumor size and avoid mastectomy (Fig. 3) (61). Taxanes and anthracyclines form the current standard of care for TNBC in both the neoadjuvant and the adjuvant settings. Epirubicin and doxorubicin are the most common anthracyclines (anticancer antibiotics known to disrupt DNA replication and mitochondrial functions to activate apoptosis) (68,69). Taxanes block angiogenesis by inhibiting epidermal growth factor receptor signaling (70).

Paclitaxel and docetaxel are familiar examples of taxanes used in the first line of therapy (71). TNBC shows a 40% pathological complete response (pCR) for taxane and anthracycline-based therapy in the neoadjuvant setting (72-74). Adjuvant therapy guidelines are usually identical for all the subtypes of breast cancer and TNBC. Chemotherapy in the adjuvant setting is recommended for tumors >0.5 cm in size, as they exhibit increased aggressiveness, with a faster growth rate and metastasis (75). Anthracycline chemotherapy (cyclophosphamide and 5-fluorouracil) in patients with metastatic TNBC exhibited a response to survival within 22 months (69). However, acute toxicity is a major concern with anthracycline-based chemotherapy (76). Metastatic patients who develop resistance to anthracycline have shown sensitivity to capecitabine, gemcitabine and vinorelbine (77-79). The combination of docetaxel with capecitabine has improved the OS of patients with metastatic TNBC (78).

Carboplatin and cisplatin are platinum salts that are used in the treatment of TNBC. These generate DNA lesions, and
apoptosis occurs in cells unable to repair these breaks (80). For TNBC, carboplatin as a neoadjuvant addition increases the response rate from 37 to 52.1% (81). A phase-II study of 86 patients evaluating the efficacy of platinum monotherapy demonstrated a 32% overall response rate (ORR) for cisplatin and 19% for carboplatin in early TNBC. Patients with BRCA1/2 mutations showed an improved response compared with patients without BRCA1/2 mutations (82). Moreover, phase-II trials showed an improved ORR of 72% in metastatic patients with BRCA mutation with neoadjuvant cisplatin monotherapy (83,84). Recently, the PEARLY trial (NCT02441933) has explored combination therapy of taxanes and carboplatin in the neoadjuvant setting (85). Carboplatin with docetaxel or paclitaxel combination has demonstrated promising efficacy in patients with TNBC and brain metastasis (86). Although TNBC is sensitive to chemotherapy, early relapse is a major concern (75). Therefore, optimizing a tailored standard regime to address chemotherapy issues, such as toxicity, and relapse has led to customizing personalized therapy based on tumor type.

7. Emerging role of targeted therapy as a strategy to treat TNBC

Therapies targeted to TNBC are being developed based on the expression of specific pathways and genes. Targeted therapy focuses on customizing cancer therapy to an individual patient's tumor (87,88). TNBC being heterogenous, targeting alterations specific to the tumor would be the most effective treatment option. A study using genomics and transcriptomics has led to identifying molecular markers that could be effectively targeted in TNBC (89). PARP inhibitors, PI3K/AKT inhibitors, and anti-androgen therapy are under clinical investigation (Fig. 3) (58).
**PARP inhibitors for patients with a BRCA1/2 mutation.** PARP is expressed in ample amounts as a nuclear enzyme that plays a critical role in DNA repair, cell proliferation, and signaling. It transfers ADP-ribose to target proteins from NAD$^+$ and ribosylates them (90). In response to DNA damage, PARP is known to activate the DNA repair process through poly (ADP)-ribosylation of multiple nuclear proteins that play a role in chromatin architecture and DNA metabolism (91). Therefore, PARP inhibition leads to the accumulation of double-strand breaks (DSBs) in cells undergoing replication. The presence of wild-type BRCA1/2 in cells results in a homologous recombination mode of repair of DSBs. However, in the cells deficient of BRCA1/2, homologous recombination is disrupted, and PARP repairs the breaks (92-94). Therefore, in these BRCA1/2-deficient cases, inhibiting PARP will result in severe, selective toxicity called 'synthetic lethality' (95). Using PARP inhibitors in treatment sensitizes the tumor cells to chemotherapy and radiotherapy, causing synthetic lethality in patients with hereditary BRCA1/2 mutations identified in several TNBC subtypes (Fig. 4A) (96).

Olaparib and talazoparib are two of the PARP inhibitors approved by the United States Food and Drug Administration (FDA) for use in patients with deficient BRCA1/2 in metastatic Her2-negative breast cancer as a single agent, based on the phase-III OlympiaAD and EMBRACA clinical trials (86-88). Patients with a germline BRCA1/2 mutation (gBRCA1/2$^+$) with metastatic breast cancer were grouped into 2:1 to olaparib vs. chemotherapy (capecitabine, eribulin, or vinorelbine) of physician's choice. The ORR was 59.9% in the TNBC patient subgroup for olaparib (n=102) and 29.9% in the case of patients who underwent chemotherapy (n=48). Olaparib showed less toxicity in tumor-grade 3 and 4 patients than the chemotherapy arm (98,99). In the EMBARCA trial (NCT01945775), gBRCA1/2$^+$ metastatic patients were given 2:1 Talazoparib 1 mg daily vs. chemotherapy of physician's choice. The ORR was 62.6% in patients given with Talazoparib (n=219) and 27.2% in patients treated with chemotherapy (n=144) (99). Several other PARP inhibitors are currently under phase-II/III clinical trials, including veliparib (NCT02163694) and niraparib (NCT01905592) (100-103).

PARP inhibitors are being investigated in combination with chemotherapy and immunotherapy. BrighTNess trial (NCT02032277) is a phase-III trial for stage-II and -III TNBC evaluating the combination of carboplatin with the PARP inhibitor veliparib followed by doxorubicin (104). The ongoing phase-I/II trial (MEDIOLA trial) involves a combination of olaparib and anti-PDL1 checkpoint inhibitor durvalumab (105). The phase-III OlympiaA trial (NCT02032823) for early TNBC is currently assessing patients with BRCA1/2 mutation treated with olaparib as monotherapy following neoadjuvant chemotherapy (106). PARTNER (NCT03150576) (107) is a phase-II/III trial that is currently ongoing checking the efficacy of olaparib and carboplatin combination in a neoadjuvant setting (107). Table II summarizes the clinical trials taken from clinicaltrials.gov.
The PI3K-AKT pathway is involved in cell growth and glucose metabolism. Under normal conditions, growth factors, such as insulin-activated receptor tyrosine kinases (RTKs) result in PI3K activation (108). This is followed by phosphorylation of phosphatidylinositol-4,5-trisphosphate (PIP2) by PI3K and conversion to phosphatidylinositol-3,4,5-trisphosphate (PIP3) (109). AKT binds to membrane-bound PIP3, bringing AKT close to phosphoinositide-dependent kinase 1 (PDK1) (110). PDK1 phosphorylates AKT resulting in the activation of multiple downstream pathways like cell growth, cell cycle, and metabolic pathways. This pathway is negatively regulated by the PTEN phosphatase (108,109,111). In TNBC, this pathway is active in 9.6% of patients due to the loss of PTEN activity (110) (Fig. 4B). Therefore, studies using PI3K inhibitors have been conducted in patients with TNBC (Table II), such as the LOTUS trial (NCT02162719), which is a phase-II trial evaluating ipatasertib in 124 patients (ORR in the PTEN low group was 48% compared with patients with PTEN expression) (112). The oral pan-PI3K inhibitor buparlisib has also been used in combination with paclitaxel in a phase-II trial (NCT01572727) involving metastatic Her2-negative patients; the ORR was 22.6% compared with placebo and paclitaxel (113). Capivasertib and AZD5363 are AKT inhibitors that are currently being investigated for PFS in patients with metastatic TNBC in the CAPltello-290 (NCT03997123) and PAKT (NCT02423603) trials, respectively (114,115). In the Phase-II trial under neoadjuvant setting, mTOR inhibitor and chemotherapy combined did not show any effect in early TNBC treatment (116). The mTOR inhibitors temsirolimus or everolimus in combination with doxorubicin and bevacizumab displayed an objective response rate of 21% in mesenchymal subtype of TNBC (117).

The AR inhibitors for AR-overexpressing TNBC. AR belongs to the nuclear steroid hormone family of receptors, is highly expressed in the LAR subtype of TNBC (118). AR antagonists have shown an effect in vitro and in vivo in the LAR type (Fig. 4C). Gucalp et al (119) used the AR inhibitor bicalutamide in a phase-II trial involving 424 AR-positive patients, which showed a clinical benefit rate of 19% and a median progression-free survival of 12 weeks (119). Among the ongoing clinical trials, Bicalutamide treatment response is being compared to standard chemotherapy in patients with metastatic TNBC in an ongoing phase-III as the first line of therapy (NCT03055312). Enzalutamide is another AR antagonist with which a phase-II trial (NCT01889238) was conducted in AR-positive patients with advanced TNBC, in which a clinical benefit of 25% was observed (120). Androgen-driven gene expression signature (Dx-signature) stratified patients into a Dx-positive and a Dx-negative group.

Figure 4. Targeted therapies currently explored for TNBC. (A) PARP inhibitors, such as olaparib and veliparib are currently under clinical trials to bring about synthetic lethality in homologous recombination-deficient TNBC harbouring BRCA1 mutations. (B) PI3K-activated TNBC with loss of PTEN can be treated with buparlisib or ipatasertib, which inhibit the PI3K enzyme. (C) In the LAR subtype of cancers, where the expression of AR is very high, AR blockers like bicalutamide and enzalutamide have made their way. (D) Antibody-drug conjugates are specific to cell-surface molecules and linked to a potent cytotoxic agent that kills the cancer cell. (E) PD-L1 blockade using atezolizumab has shown positive results in a clinical trial on patients with TNBC. AR, androgen receptor; DSBR, double-strand break; MHC, major histocompatibility complex; PARP, poly (ADP-ribose) polymerase; PD-1, programmed death-1; PD-L1, PD ligand 1; SSBR, single-strand break; TCR, T cell receptor; TNBC, triple-negative breast cancer; LAR, luminal androgen receptor; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and rad3-related protein; HR, homologous recombination; ADC, antibody-drug conjugates; TROP-2, tumour associated calcium signal transducer 2.
Table II. Summary of clinical trials of different group of inhibitors used as targeted therapy in TNBC.

| Drug                                      | Trial                      | Phase | Stage  | Disease setting                  | Results                      |
|-------------------------------------------|----------------------------|-------|--------|----------------------------------|-------------------------------|
| carboplatin + paclitaxel + veliparib       | BrightTNeSS, NCT02032277   | III   | Early  | Stage II/III TNBC                | ORR 58% vs. 53% vs. 31%      |
| carboplatin + paclitaxel + placebo        | GeparOla, NCT02789332      | II    | Early  | Stage I-III HER2 BC              | pCR 55.1% vs. 48.6%          |
| carboplatin + placebo + placebo           | NACT + carboplatin AUC2    | II    | Early  | Stage I-III gBRCA1/2m BC         | Ongoing                      |
| talazoparib                               | NCT02282345                | II    | Early  | Stage I-III gBRCA1/2m BC         | Ongoing                      |
| veliparib + carboplatin                   | I-SPY, NCT01042379         | II    | Early  | Stage II-III TNBC                | Ongoing                      |
| talazoparib vs. PCT                       | PARTNER, NCT03150576       | II/III| Early  | Stage II/III TNBC and/or gBRCAm BC | Ongoing                      |
| niraparib vs. PCT                         | BRAVO, NCT01905592         | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | ORR 62.6% vs. 27.2%          |
| veliparib + paclitaxel + carboplatin vs.  | BROCADE3, NCT02163694      | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | Ongoing                      |
| placebo + Paclitaxel + carboplatin       | TOPACIO NCT02163694        | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | Ongoing                      |
| niraparib + pembrolizumab                 | NCT03330847                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| olaparib + ceralasertib vs.               | MEDIOLA, NCT02734004       | I/II  | Advanced| gBRCAm metastatic HER-2: BC     | Ongoing                      |
| olaparib + durvalumab                     | NCT03801369                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| talazoparib + avelumab                    | NCT03330405                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| olaparib + durvalumab                     | NCT03167619                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| talazoparib + ZEN003694                   | NCT03901469                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| talazoparib                               | NCT02401347                | I/II  | Advanced| BRCA1/2 wild-type HER2: BC       | Ongoing                      |
| veliparib + cisplatin                     | NCT02595905                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| pembrolizumab + olaparib + gemcitabine    | NCT04191135                | II/III| Advanced| Metastatic TNBC                  | Ongoing                      |
| carboplatin                               | NCT02032277                | III   | Early  | Stage II/III TNBC                | ORR 58% vs. 53% vs. 31%      |
| placebo + placebo + placebo               | NACT + carboplatin AUC2    | II    | Early  | Stage I-III HER2 BC              | pCR 55.1% vs. 48.6%          |
| talazoparib                               | NCT02282345                | II    | Early  | Stage I-III gBRCA1/2m BC         | Ongoing                      |
| veliparib + carboplatin                   | I-SPY, NCT01042379         | II    | Early  | Stage II-III TNBC                | Ongoing                      |
| talazoparib vs. PCT                       | PARTNER, NCT03150576       | II/III| Early  | Stage II/III TNBC and/or gBRCAm BC | Ongoing                      |
| niraparib vs. PCT                         | BRAVO, NCT01905592         | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | ORR 62.6% vs. 27.2%          |
| veliparib + paclitaxel + carboplatin vs.  | BROCADE3, NCT02163694      | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | Ongoing                      |
| placebo + Paclitaxel + carboplatin       | TOPACIO NCT02163694        | III   | Advanced| Metastatic TNBC (gBRCA1/2+), prior lines | Ongoing                      |
| niraparib + pembrolizumab                 | NCT03330847                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| olaparib + ceralasertib vs.               | MEDIOLA, NCT02734004       | I/II  | Advanced| gBRCAm metastatic HER-2: BC     | Ongoing                      |
| olaparib + durvalumab                     | NCT03801369                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| talazoparib + avelumab                    | NCT03330405                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| olaparib + durvalumab                     | NCT03167619                | II    | Advanced| Metastatic TNBC                  | Ongoing                      |
| B. PI3K inhibitors | Drug | Phase | Stage | Disease setting | Results |
|-------------------|------|-------|-------|-----------------|---------|
|                  | ipitasertib + paclitaxel vs. placebo + paclitaxel | II    | Advanced | TNBC | ORR 40% vs. 32% |
|                  | capivasertib + paclitaxel vs. placebo + paclitaxel | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | etoposide + carboplatin | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | capivasertib + paclitaxel | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | IPI-549 + atezolizumab + bevacizumab + Nab-paclitaxel | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | gedatolisib + talazoparib | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | vistusertib + selumetinib | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | capivasertib + olaparib | II    | Metastatic | Metastatic TNBC | Ongoing |
|                  | capivasertib + ceralasertib + adavosertib + olaparib | II    | Metastatic | Metastatic TNBC | Ongoing |

| C. AR Antagonists | Drug | Phase | Stage | Disease setting | Results |
|-------------------|------|-------|-------|-----------------|---------|
|                  | enzalutamide | II    | Early | TNBC | Ongoing |
|                  | enzalutamide + paclitaxel | II    | Early | TNBC | Ongoing |
|                  | enzalutamide | II    | Advanced | Metastatic TNBC | Ongoing |
|                  | enzalutamide | II    | Advanced | Metastatic TNBC | Ongoing |
|                  | abiraterone acetate + prednisone + bicalutamide | II    | Advanced | Metastatic TNBC | Ongoing |
|                  | orteronel | II    | Advanced | Metastatic TNBC | Ongoing |
|                  | enobosarm + pembrolizumab | II    | Advanced | Metastatic TNBC | Ongoing |
|                  | bicalutamide + palbociclib | II    | Advanced | Metastatic BC | Ongoing |
|                  | bicalutamide + ribociclib | II    | Advanced | Metastatic TNBC | Ongoing |
Table II. Continued.

C, AR Antagonists

| Drug                          | Trial                         | Phase | Stage     | Disease setting | Results  |
|-------------------------------|-------------------------------|-------|-----------|-----------------|----------|
| darolutamide + capecitabine    | START, NCT03383679, NCT01990209 | II    | Advanced  | Metastatic BC   | Ongoing  |
| orteronel                     |                               | II    | Advanced  | Metastatic BC   | Ongoing  |

D, ADCs

| Drug                                                                 | Trial                        | Phase | Stage     | Disease setting | Results  |
|---------------------------------------------------------------------|------------------------------|-------|-----------|-----------------|----------|
| sacituzumab govitecan-hziy (topoisimerase-1 inhibitor SN-38), Trop2 ADC | NCT01631552                  | I/II  | Advanced  | Advanced TNBC   | ORR 33%  |
| ladiratuzumab vedotin, MMAE microtubule inhibitor, LIV-1            | NCT01969643                  | I     | Advanced  | Advanced TNBC   | ORR 25%  |
| sacituzumab govitecan chemotherapy                                   | ASCENT NCT02574455          | II    | Advanced  | Advanced TNBC   | Ongoing  |
| CAB-ROR2-ADC+BA3021                                                  | NCT03504488                  | I/II  | Metastatic| Metastatic TNBC | Ongoing  |
| SKB264                                                              | A264, NCT04152499           | I/II  | Metastatic| Metastatic TNBC | Ongoing  |
| enfentumab vedotin                                                   | EV-202, NCT04225117         | II    | Metastatic| Metastatic TNBC | Ongoing  |

E, Immune Checkpoint Inhibitors

| Drug                                                                 | Trial                        | Phase | Stage     | Disease setting | Results  |
|---------------------------------------------------------------------|------------------------------|-------|-----------|-----------------|----------|
| durvalumab + Nab-paclitaxel → EC vs. placebo + Nab-paclitaxel → EC  | GeparNuevo, NCT02685059     | II    | Early     | Stage II        | pCR 53.4% vs. 44.2% |
| Nab-paclitaxel + carboplatin + pembrolizumab → AC+ pembrolizumab vs. placebo + Nab-paclitaxel + carboplatin → AC pembrolizumab + chemotherapy vs. placebo + chemotherapy | KEYNOTE-173, NCT02622074    | I     | Early     | T2/T3 88.3%, ≥N1 66.7% | pCR 60%  |
| carboplatin + nab-paclitaxel + atezolizumab → surgery → AC/EC/FEC   | NeoTRIPaPDL1, NCT02620280    | III   | Early     | T1cN1-2 or T2-4N0-N2 | pCR 64.8% vs. 51.2% |
| pembrolizumab + paclitaxel → AC vs. placebo + Paclitaxel → AC pembrolizumab → paclitaxel → AC | ISPY-2, NCT01042379         | II    | Early     | Stage II/III    | Ongoing  |
| avelumab                                                             | SWOG1418/BR006, NCT02954874 | III   | Early     | ypT ≥1 cm or ypN1-3, TNBC | Ongoing  |
|                                                                     | A-BRAVE, NCT02926196        | III   | Early     | ypT>1 mm or ypN1-3 or IIB-III | Ongoing  |
| Drug | Trial | Phase | Stage | Disease setting | Results |
|------|-------|-------|-------|-----------------|---------|
| atezolizumab + paclitaxel + carboplatin → | NSABP B 59, NCT03281954 | III | Early | ≥ T2N0 or ≥ T1cN1 | Ongoing |
| atezolizumab + AC/EC vs. paclitaxel + carboplatin → AC/EC | | | | | |
| atezolizumab + paclitaxel → atezolizumab + AC/EC vs. paclitaxel → AC/EC | IMpassion030, NCT03498716 | III | Early | II-III | Ongoing |
| atezolizumab + Nab paclitaxel → atezolizumab + AC vs. placebo+Nab paclitaxel → placebo + AC pembrolizumab vs. PTC | IMpassion031, NCT03197935 | III | Early | cT2-cT4, cN0-cN3, cM0 | Ongoing |
| atezolizumab + Nab paclitaxel vs. placebo + Nab paclitaxel | IMpassion119, NCT02555657 | III | Advanced | Metastatic TNBC | Negative |
| pembrolizumab | IMpassion130, NCT02425891 | III | Advanced | Metastatic TNBC | OS 7.2 vs. 5.5 months |
| pembrolizumab | KEYNOTE-012, NCT01848834 | I | Advanced | Metastatic TNBC | ORR 18.5% |
| pembrolizumab | KEYNOTE-086, NCT02447003 | II | Advanced | Metastatic TNBC | ORR ~5% |
| avelumab | JAVELIN, NCT01772004 | I | Advanced | Metastatic TNBC | ORR 21.6% |
| atezolizumab | NCT01375842 | I | Advanced | Metastatic TNBC | ORR 10% |
| atezolizumab + paclitaxel vs. placebo + paclitaxel | IMpassion131, NCT03125902 | III | Metastatic | Metastatic TNBC | Ongoing |
| atezolizumab + gemcitabine + capecitabine + carboplatin vs. placebo + gemcitabine + capecitabine + carboplatin | IMpassion132, NCT03371017 | III | Metastatic | Metastatic TNBC | Ongoing |
| pembrolizumab + Nab-paclitaxel + paclitaxel + gemcitabine + carboplatin vs. placebo + Nab-paclitaxel +paclitaxel + gemcitabine + carboplatin | KEYNOTE-355, NCT02819518 | III | Metastatic | Metastatic TNBC | Ongoing |
| pembrolizumab + eribulin | ENHANCE-1, NCT02513472 | I/II | Metastatic | Metastatic TNBC | Ongoing |
| NKTR-214 | nivolumab | PIVOT-02 NCT02983045 | II | Metastatic | Metastatic TNBC | Ongoing |
| Intratumoral c-MET mRNA CAR T cells | NCT01837602 | I | Metastatic | Metastatic TNBC | Ongoing |

F, Conventional platinum agents

| Drug | Trial | Phase | Stage | Disease setting | Results |
|------|-------|-------|-------|-----------------|---------|
| carboplatin + bevacizumab + standard NAC vs. bevacizumab + standard NAC | GeparSixto, NCT01426880 | II | Early | Stage II/III/IV | pCR 53.2% vs. 36.9% |
| cisplatin + paclitaxel + everolimus vs. cisplatin + paclitaxel + placebo | NCT00930930 | II | Early | Stage II/III, TNBC | pCR 36% vs. 48% |
Dx-positive patients had an improved response to enzalutamide compared with Dx-negative patients (120,121). In AR-positive patients with early-stage TNBC, enzalutamide is currently under investigation both as a monotherapy (NCT02750358) and in combination with paclitaxel (NCT02689427). Around 40% of AR-positive TNBC patients show activation of the PI3K-AKT pathway (122). Therefore, the combined effect of enzalutamide and the PI3K inhibitor taselisib was evaluated in the TBRC032 trial (NCT02457910) where CBR was 35.7% (123). Further details are provided in Table II.

**Antibody-drug conjugates targeting surface antigens.** Antibody-drug conjugates (ADC) are made up of a linker, an inhibitor, and an antibody. The antibody is selected to be specific to cell surface molecules of cancer cells and not normal cells. The payload of cytotoxic agents must be potent to kill the cancer cell. Usually, a stable molecule is used as a linker that will bind strongly to the inhibitor (124,125) (Fig. 4D). Elevated expression of tumor-associated calcium-linked signal-transducer two cell surface glycoprotein (Trop-2) has been reported in TNBC and often correlated with poor prognosis (126). Sacituzumab Govitecan (IMMU-132) is an ADC used to target Trop-2 that delivers a topoisomerase-I inhibiting payload resulting in DSBs. Bardia et al (127) conducted a phase-I/II study involving patients with advanced-stage TNBC who had previously received two lines of treatment, and the ORR was 33.33%. A phase-III study (NCT02574455) of sacituzumab govitecan in relapsed patients with TNBC is ongoing. SKB264 is another anti-Trop2 currently under investigation in the NCT04152499 phase-I trial with metastatic TNBC patients (128). Another ADC, ladiratuzumab vedotin, an immunoglobulin G1 antibody with a microtubule inhibitor (MMAE), has shown an ORR of 25% of patients with TNBC (129).

**Inhibitors targeting other signaling pathways.** In addition to PARP and PI3K inhibitors, inhibitors of other molecular targets are being investigated in TNBC. HDAC inhibitors are currently being investigated as monotherapy (NCT02623751) and in combination with cisplatin (NCT02393794). Various Ataxia Telangiectasia and Rad3-Related Protein (ATR) and Wee inhibitors are also in clinical trials for TNBC (1). MEK inhibitors and inhibitors of cell cycle-regulating agents, such as Aurora kinase, showed antitumor effects in animal xenografts (130,131). Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was used in a phase-I study along with paclitaxel in patients with metastatic TNBC (n=9). Clinical benefit was experienced in one-third of the patients (132). BCL2 inhibitors in TNBC cell lines have shown to decrease cell proliferation (133). In TNBC cells, BCL2 expression is high (134). Therefore, BCL2 inhibitors should be further investigated for their impact as monotherapy and in combination.

**Immunotherapy as monotherapy and combination therapy for TNBC.** In the last decade, substantial evidence has been generated describing the immune system's role in guiding the disease progression of TNBC (135). It is one of the rapidly progressing areas of breast cancer research. The T cell receptor (TCR) recognizes antigen presented on major histocompatibility complex molecules by cancer cells (136).
It is followed by signaling from co-stimulatory factors such as CD28, modulated by immune-checkpoint (co-inhibitory) molecules (137). In TNBC, programmed death-ligand 1 (PD-L1) functions as a critical mediator of the balance and escape stages of cancer immunoediting (138-140). Around 20% of TNBC tumors express PD-L1, which is associated with poor prognostic features, such as higher grade, HER2-positive status, ER-negative status and large tumor size (141). Quantification of PD-L1 can be carried out on immune cells or tumor cells using immunohistochemistry (141-143). Studies have suggested that PD-L1 expression varies depending on the stage of TNBC and cell type (141-143). Expression of PD-L1 in TNBC has been associated with improved pCR (50% vs. 21%) (39,144). Along with PD-L1, TILs are also high in number in TNBC (144,145). TILs are considered to be a good prognostic marker in TNBC (146). Inhibitors of PD-L1/PD-1 block the interaction between PD-1 and PD-L1, thereby initiating a positive immune response that results in tumor killing (123). Over the last few years, immune checkpoint inhibitors (CPIs) have been in the limelight due to improved efficacy shown during clinical trials (Fig. 4E). Pembrolizumab (NCT04191135 and NCT01042379), nivolumab (NCT03181685 and NCT03414684), atezolizumab (NCT03281954 and NCT03498716) and durvalumab (NCT03167619 and NCT03616886) are some of the CPIs currently used in ongoing clinical trials for TNBC (147). The IMpassion130 trial (NCT02425891) evaluated the use of atezolizumab with paclitaxel as the first line of therapy for patients with metastatic TNBC (n=901), showing PD-L1 positivity. Atezolizumab is a PD-LA inhibitor that blocks the interaction between PD-L1 and PD-1, thereby promoting T cell activity. It is now an FDA-approved drug for PD-L1-positive patients with TNBC (148). The KEYNOTE-119 phase-III clinical trial (149) evaluated pembrolizumab’s effect as monotherapy in patients with metastatic TNBC vs. physician’s choice chemotherapy (capecitabine, vinorelbine, gemcitabine, or eribulin). The OS of this study was not encouraging (149). In the recent trial KEYNOTE-355 (NCT02819518), PD-L1-positive patients with metastatic TNBC showed improved PFS when pembrolizumab was given in combination with chemotherapy, in comparison with patients given chemotherapy alone (150). Currently, two trials, IMpassion131 (NCT03125902) and IMpassion132 (NCT03371017), are being carried out: The former is investigating the outcomes for paclitaxel and atezolizumab in untreated metastatic patients who are PD-L1 positive, while the latter is for atezolizumab along with chemotherapy (gemcitabine, capecitabine and carboplatin) in early relapsing recurrent patients with TNBC (PD-L1 positive). For early-stage breast cancer, the KEYNOTE-173 phase-Ib trial evaluated pembrolizumab along with taxane and anthracycline neoadjuvant therapy, which resulted in an ORR of 100% (151). The ISPY-2 trial was a phase-III trial evaluating pembrolizumab in combination with chemotherapy (vs. placebo) in patients with stage-II/III TNBC, which demonstrated an ORR of 60 and 20%, respectively (152). The SWOG S1418 (NCT02954874) trial is investigating anti-PD-L1/PD-L1 in the adjuvant setting for a year in order to determine whether there is an improvement in DFS. The NSABP B-59 (NCT03281954) and IMpassion030 (NCT03498716) trials are addressing whether the combination of neoadjuvant/adjuvant chemotherapy and atezolizumab might improve DFS compared with chemotherapy alone (153).

### Table III. Role of miRNA and lncRNA expressed in triple negative breast cancer.

#### A, miRNA

| First author, year | Names | Role in TNBC | (Refs.) |
|--------------------|-------|--------------|--------|
| Gorur et al, 2021; Pang et al, 2018; | miR-22 and miR-200 family, miR-190a, miR-136-5p, miR-126-5p, miR-135b-5p, miR-182-5p | Epithelial-to-mesenchymal transition | (159,160) |
| Lyng et al, 2012 | | Tumorigenesis | (158) |
| Huang et al, 2013; Tormo et al, 2019 | miR-95, miR-449, and miR15a/16 | Drug resistance | (161,162) |

#### B, lncRNA

| First author, year | Names | Role in TNBC | (Refs.) |
|--------------------|-------|--------------|--------|
| Lin et al, 2016 | LINKA | Glycolysis and tumorigenesis | (170) |
| Jiang et al, 2018; Ke et al, 2016 | NEAT1 | Migration, invasion and apoptosis | (172,173) |
| Yang et al, 2019 | POU3F3 | Inhibits apoptosis | (171) |
| Sha et al, 2017 | DANCRC | Inhibits apoptosis | (177) |

miR/miRNA, microRNA; TNBC, triple-negative breast cancer; LINKA, long intergenic non-coding RNA for kinase activation; NEAT1, nuclear paraspeckle assembly transcript 1; POU3F3, POU domain class 3 transcription factor 3; differentiation antagonizing non-protein coding RNA; DANCRC, differentiation antagonizing nonprotein coding RNA.
8. Non-coding RNA as therapy

Sequencing of all the RNA species in a given cell using RNA-seq identified several RNA species, including mRNA. The two major classes of non-coding RNA studied in TNBC development and treatment are miRNA and Long non-coding RNA.

MicroRNA (miRNA/miR) is a small non-coding RNA, usually 20-22 nucleotides in length, regulating gene expression. miRNA is known to bind to the 3’ untranslated region of mRNA. This binding either degrades mRNA or represses translation (154). miRNA is a key player in tumorigenesis, stemness, and drug resistance in TNBC (155-157). For instance, tumour suppressor miRNAs, involved in tumour development, miR-190a, miR-136-5p, miR-126-5p, miR-135b-5p and miR-182-5p are downregulated in TNBC (158). miR-22 is downregulation in TNBC, is associated with migration and metastasis. miR-22 exerts its effect through eukaryotic elongation factor 2 kinase (eEF2K) expression, which activates PI3K signaling pathway (159). Also, oncosupressor, miR-200b, activates target genes like SRY-box transcription factor 2 (SOX2), CD133, and zinc finger E-box binding homeobox 1 (ZEB1), aiding in migration and invasion and stemness (157,160). High expression of miR-95 in TNBC indicates radiotherapy resistance that occurs by targeting sphingosine-1-phosphate signaling (161). Downregulated miR-449 upregulates CDK2, CCNE2 causing doxorubicin resistance in TNBC (162,163) (Table III). Multiple studies also show that miRNAs are expressed in different stages of TNBC Multiple studies also show that miRNAs are expressed in different stages of TNBC (164-166). These studies give hope for miRNA-based therapies, as the use of miRNA mimics or inhibitor oligonucleotides could serve as a therapeutic approach for TNBC (167). A study conducted by Shu et al (168) used miR-21 combined with aptamer targeting EGFR, blocking tumor growth in murine models. Yin et al (169) designed an RNA aptamer bound to CD133 with a sequence complementary to miR-21 carried by a three-way junction motif scaffold that reduced cell migration in TNBC cells (169). Non-coding RNA is being pursued as one of the TNBC therapy.

IncRNA (long non-coding RNA), ~200 nucleotides in length, regulates gene expression at the epigenetic, transcription, post-transcription levels, and post-translation modification (16). The long intergenic non-coding RNA for kinase activation activates HIF-1α by phosphorylating it via leucine-rich repeat kinase 2 to promote glycolysis and tumorigenesis in TNBC (170). Yang et al (171) demonstrated the involvement of POU domain class 3 transcription factor 3 (POU3F3) in inhibiting apoptosis and promoting proliferation in TNBC (171). Nuclear paraspeckle assembly transcript 1 (NEAT1) plays a role in TNBC metastasis (172-174). Some IncRNAs (HOTAIR, LncRNA-ATB, LincRNA-ROR) are known to be co-expressed with transcription factors involved in EMT and proliferation (175). Vaidya et al (176) demonstrated that nanoparticle-mediated transfer of RNA interference molecules targeting differentiation antagonizing non-protein coding RNA, a lncRNA that is enriched in TNBC, showed some efficacy in a murine xenograft model of TNBC (Table III). These studies have shed light on the use of antisense oligonucleotides against oncogenic IncRNA as a potential approach to TNBC therapy.

9. Conclusions

TNBC is associated with poor prognosis compared to other breast cancer subtypes, and its treatment remains challenging. New technology and tools have provided insight into the molecular mechanism of the disease. This knowledge has led to the identification of druggable targets and the development of biomarker-driven therapy. The FDA-approved drugs for TNBC to date include PARP inhibitors for patients with BRCA1/2 mutations and avelozulizumab for PD-L1+ tumors. Emerging targeted therapies have given hope for the treatment of TNBC. The inclusion of immunotherapy has shown promising results. Additionally, attempts to identify combinations that work effectively against TNBC are ongoing. A combination of the molecular profiles, including non-coding RNA and histology, has improved the prognosis and guided the treatment for TNBC.

Acknowledgements

The authors would like to thank Dr Raksha Rao K. (Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka, India) for the critical reading of the manuscript and suggestions.

Funding

Financial support was provided by The Department of Science and Technology Fund for Improvement of S&T Infrastructure in Higher Educational Institutions (grant no.SR/FST/LSI-5361/2012), The Department of Biotechnology, India, Glue grant (BTIPR23078/MED/29/1253/2017), and The Departments Information Technology, Biotechnology and Science and Technology, Government of Karnataka, India. MM is supported by The Senior Research Fellowship from Department of Science and Technology-Innovation in Science Pursuit for Inspired Research, India (DST/INSPIRE Fellowship/2016/IFI60535).

Availability of data and materials

Not applicable.

Authors’ contributions

MM and BC conceived the article, performed the literature search and data analysis, drafted and critically revised the work, and confirm the authenticity of the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Hwang SY, Park S and Kwon Y: Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 199: 30-57, 2019.

2. Sung H, Ferlay J, Mery RD, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin: Feb 4, 2021 (Epub ahead of print). doi: 10.3322/caac.21660.

3. Venu CM, Sotie T, Elsen MB, van de Rijn M, Jeffrey S and Rees C: Molecular portraits of human breast tumors. Nature 406: 747-52, 2000.

4. Pena‑Llortca F and Viale G: Pathological and molecular diagnostic of triple-negative breast cancer: A clinical perspective. Ann Oncol 23: vi19-vi122, 2012.

5. Yeh IT and Mies C: Application of immunohistochemistry to breast cancer. Arch Pathol Lab Med 132: 349-358, 2008.

6. Fedele M, Cerchia L and Chiappetta G: The epithelial‑to‑mesenchymal transition in breast cancer: Focus on basal-like carcinomas. Cancers 13: 194, 2017.

7. Dias K, Dvorik‑Gheva A, Hallett RM, Wu Y, Hassan J, Pond GR, Levine M, Whelan T and Bane AL: Claudin‑low breast cancer: clinical & pathological characteristics. PLOS One 12: e0168669, 2017.

8. Spigel DR and Burstine HJ: HER2 overexpression metastatic breast cancer: Current Treat Options Oncol 3: 163-174, 2022.

9. Sotiriou C, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.

10. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Allen KT, Olopade OI, Dresdner L, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96, 2006.

11. Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, Chen Y, Cao L, Xu Q, Du X and Yang W: Gene expression profiling for diagnosis of triple-negative breast cancer: A multicenter, retrospective cohort study. Front Oncol 9: 354, 2019.

12. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Trastuzumab after adjuvant chemotherapy in HER2‑positive breast cancer. N Engl J Med 362: 1273-1282, 2011.

13. Marotti JD, de Abreu FB, Wells WA and Tsongalis GJ: Recent treatment progress of triple negative breast cancer. Breast Cancer Res Treat 144: 539-549, 2015.

14. Regan C, Mier P, Ng JS, Muller M, Chen Y and De Neve J: The spectrum of triple-negative breast disease: High‑and low‑grade lesions. Am J Pathol 187: 2133-2138, 2017.

15. Reis‑Filho JS and Butt ANE: Triple negative tumours: A critical review. Histopathology 52: 108‑118, 2008.

16. Kaplan HG, Malmgren JA and Atwood M: TN10 triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy. Breast 15: 454-460, 2009.

17. Chang‑Qing Y, Jie L, Shi‑Qi Z, Kun Z, Zhi‑Qian G, Ran X, Hui‑Meng L, Ren‑Bin Z, Gang Z, Da‑Chuan Y and Chen‑Yan Z: Recent treatment progress of triple negative breast cancer. Prog Natl Acad Sci USA 106: 14155-14156, 2009.

18. Weigelt B and Reis‑Filho JS: Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat Rev Clin Oncol 6: 718, 2009.

19. Shah SP, Roth A, Goya R, Oloomi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Shah SP, Roth A, Goya R, Band H and Band V: Histological, molecular and functional subtypes of breast cancers. Cancer Biol Res 22: 61, 2020.

20. Romero P, Benhamo V, Deniziat G, Fuhrmann L, Berger F, Mantel E, Buhler J, Vacher S, Laurent C, Marangoni E, et al: Medullary breast carcinoma, a triple-negative breast cancer associated with BCLG overexpression. Am J Pathol 188: 2378‑2391, 2018.

21. Huober J, Gelbrich M, Thurlimann B, Fedele M, Cerchia L and Chiappetta G: Characterization of a naturally occurring breast cancer subset enriched in epithelial‑to‑mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116‑4124, 2009.

22. Ahn SG, Kim SJ, Kim C and Jeong J: Molecular classification of triple-negative breast cancer. J Breast Cancer 19: 223-230, 2016.

23. Liu YR, Jiang YZ, Xin Y, Xu X, Luo W, Zhao J, Liu Y, Su J, Liu SY, et al: Comprehensive transcriptional analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res Treat 18: 35, 2016.

24. Mackey J, Glaspy J, Chan A, Pawlicki M, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 362: 1273-1282, 2011.

25. Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.

26. Hallgren SW, Bergh J, Widén M, Pettersson T, Bergström R, Lilja H and Olsson H: Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 220: 562‑573, 2010.

27. Lu L, Wu N, Li F, Li L, Wei L and Liu J: Clinicopathological and molecular characteristics of 44 patients with pure secretory breast carcinoma. Cancer Biol Med 16: 139, 2019.

28. Geyer FC, Geyer FC, Marchio C, Burke KA, Weigelt B and Reis‑Filho JS: Triple-negative breast cancer: The importance of molecular and histological subtyping, and recognition of low‑grade variants. NPI Breast Cancer 2: 16036, 2016.

29. Kuroda H, Sakamoto G, Omihara K, and Yotama S: Clinical and pathological features of glycogen-rich cell breast carcinoma of the breast. Breast Cancer 12: 199‑205, 2005.

30. Geyer FC, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 362: 1273-1282, 2011.

31. Park M, Cai Y, Buisseret L, Salgado R, Van den Eyden G, Haibe‑Kains B and Reis‑Filho JS: The spectrum of triple-negative breast disease: High- and low-grade lesions. Am J Pathol 187: 2133-2138, 2017.

32. Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Staallings‑Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K and Visscher DW: Immune cell quantification in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat 144: 539-549, 2014.

33. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Maris S, Alhava E and Syyränen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28: 859‑864, 1992.

34. Matsumoto H, Koo S, Dent R, Tan PH and Iqbal J: Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 68: 506‑510, 2015.

35. Fridman WH, Galon J, Pagès F, Tartour E, Sautès‑Fridman C, Kirnbauer R, Mlecnik B, Dupuy A, Bettega MC, Berthezene X, et al: The immune and inflammatory infiltrate in breast cancer: Analysis of prognostic role and relations with the tumor microenvironment. J Pathol 228: 323‑336, 2012.

36. Wang L, Wang X, Li Y, Liu H, Liu J, Li J, Xue F, et al: Expression of immunosuppressive molecules is associated with a high‑grade intratumoral lymphocyte‑rich phenotype in primary breast cancer. Am J Pathol 185: 1538‑7445.SABCS16‑S1‑07

37. Sänger N, El‑Balat A, Holtrich U, Marchiò C, Burke KA, Weigelt B and Reis‑Filho JS: Triple-negative breast cancer: The importance of molecular and histological subtyping, and recognition of low‑grade variants. NPI Breast Cancer 2: 16036, 2016.

38. Kuroda H, Sakamoto G, Ohmihara K, and Yotama S: Clinical and pathological features of glycogen-rich cell breast carcinoma of the breast. Breast Cancer 12: 199‑205, 2005.
47. Curtis C, Shah SP, Chin SF, Tursahvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samuraiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast cancers informs new insights and therapeutic opportunities. Nature 542: 406–413, 2016.

48. Venkitaraman AR: Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Ann Rev Pathol 4: 461–487, 2009.

49. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, González‑Angulo AM, Hortobagyi GN and Arun BK: Clinical and pathological characteristics of BRCA1 and BRCA2 breast cancers. J Clin Oncol 26: 4282–4288, 2008.

50. Foulkes WD, Stefanoff JM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M and Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95: 1482–1485, 2003.

51. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70, 2012.

52. Antoniou A, Pharaoh PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130, 2003.

53. Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAiness’ in sporadic cancers. Nat Rev Cancer 4: 814‑819, 2004.

54. Lord CJ and Ashworth A: BRCAness revisited. Nat Rev Cancer 16: 110‑120, 2016.

55. Bertucci F, Ng CK, Patsouris A, Droin N, Picciolo S, Carubbia N, Soria JC, Dien AD, Adnani Y, Kamal M, et al: Genomic characterization of metastatic breast cancers. Nat Genet 46: 560‑566, 2014.

56. Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, et al: Genomic and transcriptomic landscape of triple‑negative breast cancers: Subtypes and treatment strategies. Cancer Cell 35: 428‑440.e5, 2019.

57. Nik‑Zainal S, Davies H, Staf J, Ramakrishna M, Goddik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al: Landscape of somatic mutations in 560 breast cancer whole‑genome sequences. Nature 534: 47‑54, 2016.

58. Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple‑negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13: 674‑690, 2016.

59. Zhao Y, Sheng M, Zheng L, Xiong D, Yang K and Luo Y: Application of circulating tumour DNA in breast cancer. Breast J 26: 1797‑1800, 2020.

60. Lustberg MB, Stover DG and Chalmers JJ: Implementing liquid biopsies in clinical trials: State of affairs, opportunities and challenges. Cancer J 24: 61‑64, 2018.

61. Thompson AM and Moulder‑Thompson SL: Neoadjuvant treatment of breast cancer. Ann Oncol 23 (Suppl 10): x231‑x236, 2012.

62. Cristofanilli M, Pierga JY, Reuben J, Batham S, Lee FY and Rademaker A: Multidisciplinary management of breast cancer (TNBC): Preplanned correlative results from clinical trials of new agents in early‑stage triple‑negative breast cancer. Ann Oncol 26: 547‑549, 2015.

63. Bachelová LS, Makower DF and Sparano JAJ: Taxanes: Impact on breast cancer therapy. Anticancer Drugs 25: 512‑521, 2014.

64. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnotte H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long‑term clinical benefit in breast cancer. J COBE/CoC pooled analysis. Lancet 384: 164‑172, 2014.

65. Von Minckwitz G, Untch M, Blomher JU, Costa SD, Eitdmt H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huoel J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796‑1804, 2012.

66. Liedtke C, Mazouni C, Hess KR, Andrie F, Tordai A, Mejia JA, Symmans WF, Gonzalez‑Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long‑term survival in patients with triple‑negative breast cancer. J Clin Oncol 26: 1275‑1281, 2008.

67. Park JH, Ahn JH and Kim SB: How shall we treat early‑triple‑negative breast cancer (TNBC): From the current standard to upcoming immunomolecular‑strategies. ESMO Open 3: 0001358, 2018.

68. Greene J and Hennessy B: The role of anthracyclines in the treatment of early breast cancer. J Oncol Pract 21: 201‑212, 2015.

69. Park JS, Jeung HC, Rha SY, Ahn JH, Kang B, Chon HI, Hong MH, Lim S, Yang WI, Nam CM and Chung HC: Phase II gemcitabine and capcitabine in combination with paclitaxel for metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol 74: 799‑808, 2014.

70. Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitriaki E, Kontopidis E, Bozioleoulou V, Kalokyaki A, Georgoulivas V and Mavridou D: A multicenter phase II trial of docetaxel and capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 70: 167‑176, 2012.

71. Anton A, Luch A, Casado A, Provenzo M, Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J and Martin M: Phase I study of oral vinorelbine and capcitabine in patients with metastatic breast cancer. Anticancer Res 30: 2255‑2261, 2010.

72. Kennedy RD, Quinne JJ, Mullan PB, Johnston PG and Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96: 1659‑1668, 2004.

73. Huang L, Liu Q, Chen Z, Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Oncol Targets Ther 10: 5739‑5744, 2017.

74. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, et al: TBCR009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple‑negative breast cancer. J Clin Oncol 33: 1902‑1909, 2015.

75. Byrski T, Dent R, Blecharz P, Foszczyńska‑Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, et al: Results of a phase II open‑label, non‑randomized trial of cisplatin weekly with paclitaxel as neoadjuvant chemotherapy in patients with BRCA1‑positive metastatic breast cancer. Breast Cancer Res 14: R110, 2012.

76. Isakoff SJ: Triple negative breast cancer: Role of specific chemotherapy agents. Cancer J 16: 53‑61, 2010.

77. Kim GM, Jeung HC, Jung KH, Kim HJ, Lee KH, Park KH, Lee JE, Anh MS, Kohn S, Lee SJ, et al: PEARLY: A randomized, multicenter, open‑label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early‑triple‑negative breast cancer. J Clin Oncol 35: (15_suppl): 2948‑TPS587, 2017.

78. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ and Shen KW: Weekly paclitaxel plus carboplatin is an effective nonanthracycline‑containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 21: 961‑967, 2010.

79. Ashcroft C: Targeted and combination therapy. Nature 472: 294‑297, 2004.

80. Daney CE and Chen XK: Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Disc 5: 649‑659, 2006.
89. Jhan JR and Andtreech ER: Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 18: 1595‑1609, 2017.
90. Andberith M, Salles B and Calsou P: Involvement of poly (ADP‑ribose) polymerase‑1 and XRCCI/DNA ligase III in an alternative route for DNA double‑strand breaks rejoining. J Biol Chem 279: 55117‑55126, 2004.
91. Shall S and de Murcia G: Poly(ADP‑ribose) polymerase‑1: What have we learned from the deficient mouse model? Mutat Res 646: 1‑13, 2007.
92. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knight A, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 454: 912‑917, 2008.
93. Bryant HE, Schultz N, Parker PA, Lord CJ, Xu Y, Tepper K, Meric‑Bernstam F, Hess KR, Herbrich SM, Valero V, et al: Specific killing of BRCA2‑deficient tumours with inhibitors of poly(ADP‑ribose) polymerase. Nature 434: 913‑917, 2005.
94. Turner N, Tutt A and Ashworth A: Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5: 388‑393, 2005.
95. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN and Ashworth A: A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27: 1368‑1377, 2008.
96. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan‑Koch S, Durakcz BW, Hostomsky Z, Kumpf RA, Kyle S, et al: Anticancer chemosensitization and radiosensitization by the novel poly(ADP‑ribose) polymerase‑1 inhibitor KU0059436. J Biol Chem 281: 56‑67, 2006.
97. Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloye S, Li W, Turner N, Tutt A and Ashworth A: Final overall survival and tolerability results: Olaparib versus chemotherapy for patients with germline BRCA2 mutation and HER2‑negative metastatic breast cancer (BR21). J Clin Oncol 35: 2017.
98. Robson ME, Tung NM, Chan A, Díaz L, O'Shaughnessy J, Rugo H, Manikas A, Shikhaliev B, Krivokopytova P, Batista L, Campone M, et al: A randomized adaptive phase II/III study of buparlisib and paclitaxel in first‑line treatment of patients with metastatic triple‑negative breast cancer (CAPTCHLo290). J Clin Oncol 38: TPS1109, 2020.
99. Schmid P, Abraham J, Chan S, Wheatley D, Brun T, Nemesadzé G, Baird R, Park YH, Hall P, Perren T, et al: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first‑line therapy for metastatic triple‑negative breast cancer (PAKt): A randomized, double‑blind, placebo‑controlled, phase II trial. J Clin Oncol 36: 1007, 2018.
100. Gonzalez‑Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Valero Brewster V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, et al: Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (F‑FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR‑FEC) in women with triple‑receptor‑negative breast cancer (TNBC). J Clin Oncol 38: 28: 313‑320, 2020.
101. Kinch L, Chouvet G, Canfield J, Bidard F, Davis S, Petrelli N, Sposto R, et al: Targeting the PI3K/AKT/mTOR pathway in the treatment of mesenchymal‑triple‑negative breast cancer: Evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 3: 509‑515, 2017.
102. Kim Y, Jang H, Park J, Kwon B, Yim M, Kim J, et al: Lowering of androgen receptor expression on the survival outcomes in breast cancer: A meta‑analysis. J Breast Cancer 18: 134‑142, 2015.
103. Guclalp A, Tolaney S, Isakov SJ, Jingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al: Targeting the PI3K/AKT/mTOR pathway in patients with triple‑negative breast cancer: Final efficacy results of doss1 Oncology Group BRE09‑146. J Clin Oncol 33: 1082, 2015.
104. Isakov SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Tellin ML, Díaz R, Han HS, Garber JE, et al: A randomized phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 mutation‑positive breast cancer: Design and rationale. Future Oncol 13: 307‑320, 2017.
105. Zimmer AS, Gillard M, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3‑kinases: Implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615‑675, 2001.
106. Roylance R, Johnstone R, Topalova P, Blau S, Tan AR, Isakov SJ, Oliveira M, Saura C, Wongchenko MJ, et al: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first‑line therapy for metastatic triple‑negative breast cancer (LOTUS): A multicentre, randomised, double‑blind, placebo‑controlled, phase 2 trial. Lancet Oncol 18: 1293‑1307, 2017.
107. Catley M, Okkenhaug K, Ahmed K, White S, Timmis J and Waterfield MD: Cellular function of phosphoinositide 3‑kinases: Implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615‑675, 2001.
108. Kim SB, Dent R, Im SA, Espie M, Blau S, Tan AR, Isakov SJ, Oliveira M, Saura C, Wongchenko MJ, et al: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first‑line therapy for metastatic triple‑negative breast cancer (LOTUS): A multicentre, randomised, double‑blind, placebo‑controlled, phase 2 trial. Lancet Oncol 18: 1293‑1307, 2017.
109. Catley M, Okkenhaug K, Ahmed K, White S, Timmis J and Waterfield MD: Cellular function of phosphoinositide 3‑kinases: Implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615‑675, 2001.
110. Roylance R, Johnstone R, Topalova P, Blau S, Tan AR, Isakov SJ, Oliveira M, Saura C, Wongchenko MJ, et al: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first‑line therapy for metastatic triple‑negative breast cancer (LOTUS): A multicentre, randomised, double‑blind, placebo‑controlled, phase 2 trial. Lancet Oncol 18: 1293‑1307, 2017.
111. Catley M, Okkenhaug K, Ahmed K, White S, Timmis J and Waterfield MD: Cellular function of phosphoinositide 3‑kinases: Implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615‑675, 2001.
112. Roylance R, Johnstone R, Topalova P, Blau S, Tan AR, Isakov SJ, Oliveira M, Saura C, Wongchenko MJ, et al: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first‑line therapy for metastatic triple‑negative breast cancer (LOTUS): A multicentre, randomised, double‑blind, placebo‑controlled, phase 2 trial. Lancet Oncol 18: 1293‑1307, 2017.
miRNAs involv ed in carcino genes is , progn os is ,

Mittendorf EA, Philips AV, Meric-Bernstam F, cancer. Oncotarget 6: 5449‑5464, 2015.

Sabatier R, Finetti P, Mamessier E, Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK: Nat Rev Drug Dis 14: 561‑584, 2015.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA and Ditzel HJ: Global microRNA expression profiling of high‑risk ER+ breast cancers from patients receiving adjuvant tamoxifen therapy. Clin Cancer Res 11: 2693‑2703, 2012.

Prehn JH: Systems modeling accurately predicts responses to Palbociclib‑Letrozol‑Kombination. Breast Cancer 375: 657‑667, 2018.

Finn RS: Östrogenrezeptor‑positiver Brustkrebs: Erfolgreiche IMpassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 37 (Suppl 15): S1003, 2019.

Kortés J, Lipatov O, Im SA, Gonçalves A, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohhtani S, et al: LBA21: KEYNOTE‑119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) 38 (12): 2015‑018. Mol Cancer Res 13: 689‑700, 2015.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, et al: IMPassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Ann Oncol 31: 369‑380, 2020.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA and Dieras V, Molinero L, Chui SY, et al: IMPassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Ann Oncol 30: v859‑v860, 2019.

Corrêa, D, Guo Z, Karantza V and Aktan G: Abstract CT006: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, incompletely resectable, or metastatic triple-negative breast cancer (mTNBC). Cancer Res: 77, 2017 doi: 10.1158/1538-7445.AM2017-CT006.

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 31: 569‑581, 2020.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA and Dieras V, Molinero L, Chui SY, et al: IMPassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Ann Oncol 30: v859‑v860, 2019.

Corrêa, D, Guo Z, Karantza V and Aktan G: Abstract CT006: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, incompletely resectable, or metastatic triple-negative breast cancer (mTNBC). Cancer Res: 77, 2017 doi: 10.1158/1538-7445.AM2017-CT006.

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 31: 569‑581, 2020.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA and Dieras V, Molinero L, Chui SY, et al: IMPassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Ann Oncol 30: v859‑v860, 2019.

Corrêa, D, Guo Z, Karantza V and Aktan G: Abstract CT006: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, incompletely resectable, or metastatic triple-negative breast cancer (mTNBC). Cancer Res: 77, 2017 doi: 10.1158/1538-7445.AM2017-CT006.

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 31: 569‑581, 2020.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA and Dieras V, Molinero L, Chui SY, et al: IMPassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) nab-paclitaxel (nPa) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Ann Oncol 30: v859‑v860, 2019.

Corrêa, D, Guo Z, Karantza V and Aktan G: Abstract CT006: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, incompletely resectable, or metastatic triple-negative breast cancer (mTNBC). Cancer Res: 77, 2017 doi: 10.1158/1538-7445.AM2017-CT006.

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 31: 569‑581, 2020.
163. Naorem LD, Muthaiyan M and Venkatesan A: Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach. J Cell Physiol 234: 11768-11779, 2019.

164. Malla RR, Kumari S, Gavara MM, Badana AK, Gugalavath S, Kumar DKG and Rokkam P: A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer. Biophys Rev 11: 227-234, 2019.

165. Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J, Ye F, Guo X, Zheng W, Zheng Y and Shu XO: Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res Treat 152: 183-191, 2015.

166. Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C, Kern F, Kohlhaas J, Schrörs H, Saiz A, Zabler C, et al: MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Sci Rep 8: 11584, 2018.

167. Mei J, Hao L, Wang H, Xu R, Liu Y, Zhu Y and Liu C: Systematic characterization of non-coding RNAs in triple-negative breast cancer. Cell Prolif 53: e12801, 2020.

168. Shu D, Li H, Shu Y, Xiong G, Carson WE III, Haque F, Xu R and Guo P: Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9: 9731-9740, 2015.

169. Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P and Shu D: Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD133. Mol Thera 27: 1252-1261, 2019.

170. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, et al: The LINK-A IncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol 18: 213-224, 2016.

171. Yang J, Meng X, Yu Y, Pan L, Zheng Q and Lin W: LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9. Biosci Biotechnol Biochem 83: 1117-1123, 2019.

172. Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol 233: 8558-8566, 2018.

173. Ke H, Zhao L, Feng X, Xu H, Zou L, Yang Q, Su X, Peng L and Jiao B: NEAT1 is required for survival of breast cancer cells through FUS and miR-548. Gene Regul Syst Biol 10 (Suppl 1): S11-S17, 2016.

174. Wang LI, Liu D, Wu X, Zeng Y, Li L, Hou Y, Li W and Liu Z: Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research. J Cell Physiol 233: 6603-6612, 2018.

175. Xu Q, Deng F, Qin Y, Zhao Z, Wu Z, Xing Z, Ji A and Wang QJ: Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis. Cell Death Dis 7: e2254, 2016.

176. Vaidya AM, Sun Z, Ayat N, Schilb A, Liu X, Jiang H, Sun D, Scheidt J, Qian V, He S, et al: Systemic delivery of tumor-targeting siRNA nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy. Bioconjug Chem 30: 907-919, 2019.

177. Sha S, Yuan D, Liu Y, Han B and Zhong N: Targeting long non-coding RNA DANC in inhibits triple negative breast cancer progression. Biol Open 6: 1310-1316, 2017.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.